The effect of cardiac resynchronisation therapy upgrade from right ventricular pacing on symptoms and functional clinical outcomes, results from the BUDAPEST-CRT Upgrade trial
Abstract Background Based on the results of the BUDAPEST-CRT Upgrade trial, in patients with intermittent or permanent right ventricular (RV) pacing and reduced left ventricular ejection fraction (HFrEF) upgrade to cardiac resynchronization therapy (CRT) reduces morbidity and mortality. Purpose Whet...
Saved in:
Published in | Europace (London, England) Vol. 26; no. Supplement_1 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
24.05.2024
|
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
Background
Based on the results of the BUDAPEST-CRT Upgrade trial, in patients with intermittent or permanent right ventricular (RV) pacing and reduced left ventricular ejection fraction (HFrEF) upgrade to cardiac resynchronization therapy (CRT) reduces morbidity and mortality.
Purpose
Whether the substantial treatment effect of the CRT upgrade could also be detected in a better functional and exercise capacity is scarcely investigated. We examined the changes of the prespecified tertiary endpoints such as symptoms, quality of life (QoL), exercise capacity and natriuretic peptide measurement from baseline to 12 months.
Methods
In the BUDAPEST CRT Upgrade trial 360 HFrEF patients with a priorly implanted PM or ICD and >20% of RV pacing burden were randomly assigned to CRT-D upgrade (n=215) or ICD (n=145) in a 3:2 ratio. The prespecified tertiary endpoints were changes in quality of life measured by EQ-5D-3L, New York Heart Association (NYHA) functional class, 6-minute walk test (6-MWT), and NT-proBNP. When data of trial patients were unavailable due to death at 12 months, imputed values were used as 0 (6MWT) and 0 score (EQ-5D-3L) or a 5th grade (NYHA class). Responders were defined as >15% change of left ventricular end-systolic volume at 12 months.
Results
From baseline to 12 months, NYHA functional class improved in the CRT-D upgrade arm compared with the ICD only group [adjusted odds ratio (OR) 0.50; 95% CI 0.32-0.80; P=0.003]. According to the adjusted model there was a statistically significant decrease in the NT-proBNP [adjusted difference -1257 pg/mL; 95% CI -2287 – (-228); P=0.017]. In responders, the changes in NT-proBNP levels were significantly greater than in non-responders [adjusted difference -1635 pg/mL; 95% CI -2811 - (-459); P=0.007]. The progression of worsening of QoL attributed to ageing was moderated only by CRT-D upgrade [EQ-5D-3L difference by age -0.01; 95% CI -0.02 - (-0.003); P=0.004; interaction P=0.003]. 6MWT did not improve significantly in either group.
Conclusions
Patients receiving CRT upgrade showed a substantial improvement in symptoms and a significant decrease in natriuretic peptide levels, as compared to ICD alone, which was more pronounced in responders. Moreover, CRT-D upgrade could moderate the progression of worsening of quality of life attributed to ageing in this vulnerable, older patient population. |
---|---|
AbstractList | Abstract
Background
Based on the results of the BUDAPEST-CRT Upgrade trial, in patients with intermittent or permanent right ventricular (RV) pacing and reduced left ventricular ejection fraction (HFrEF) upgrade to cardiac resynchronization therapy (CRT) reduces morbidity and mortality.
Purpose
Whether the substantial treatment effect of the CRT upgrade could also be detected in a better functional and exercise capacity is scarcely investigated. We examined the changes of the prespecified tertiary endpoints such as symptoms, quality of life (QoL), exercise capacity and natriuretic peptide measurement from baseline to 12 months.
Methods
In the BUDAPEST CRT Upgrade trial 360 HFrEF patients with a priorly implanted PM or ICD and >20% of RV pacing burden were randomly assigned to CRT-D upgrade (n=215) or ICD (n=145) in a 3:2 ratio. The prespecified tertiary endpoints were changes in quality of life measured by EQ-5D-3L, New York Heart Association (NYHA) functional class, 6-minute walk test (6-MWT), and NT-proBNP. When data of trial patients were unavailable due to death at 12 months, imputed values were used as 0 (6MWT) and 0 score (EQ-5D-3L) or a 5th grade (NYHA class). Responders were defined as >15% change of left ventricular end-systolic volume at 12 months.
Results
From baseline to 12 months, NYHA functional class improved in the CRT-D upgrade arm compared with the ICD only group [adjusted odds ratio (OR) 0.50; 95% CI 0.32-0.80; P=0.003]. According to the adjusted model there was a statistically significant decrease in the NT-proBNP [adjusted difference -1257 pg/mL; 95% CI -2287 – (-228); P=0.017]. In responders, the changes in NT-proBNP levels were significantly greater than in non-responders [adjusted difference -1635 pg/mL; 95% CI -2811 - (-459); P=0.007]. The progression of worsening of QoL attributed to ageing was moderated only by CRT-D upgrade [EQ-5D-3L difference by age -0.01; 95% CI -0.02 - (-0.003); P=0.004; interaction P=0.003]. 6MWT did not improve significantly in either group.
Conclusions
Patients receiving CRT upgrade showed a substantial improvement in symptoms and a significant decrease in natriuretic peptide levels, as compared to ICD alone, which was more pronounced in responders. Moreover, CRT-D upgrade could moderate the progression of worsening of quality of life attributed to ageing in this vulnerable, older patient population. |
Author | Behon, A Schwertner, W R Zima, E D Kosztin, A Goscinska-Bis, K Merkel, E D Hatala, R Kutyifa, V Szigeti, M Kovacs, A Lakatos, B K Solomon, S D Molnar, L Merkely, B K |
Author_xml | – sequence: 1 givenname: E D surname: Merkel fullname: Merkel, E D – sequence: 2 givenname: R surname: Hatala fullname: Hatala, R – sequence: 3 givenname: M surname: Szigeti fullname: Szigeti, M – sequence: 4 givenname: W R surname: Schwertner fullname: Schwertner, W R – sequence: 5 givenname: B K surname: Lakatos fullname: Lakatos, B K – sequence: 6 givenname: A surname: Behon fullname: Behon, A – sequence: 7 givenname: E D surname: Zima fullname: Zima, E D – sequence: 8 givenname: L surname: Molnar fullname: Molnar, L – sequence: 9 givenname: K surname: Goscinska-Bis fullname: Goscinska-Bis, K – sequence: 10 givenname: S D surname: Solomon fullname: Solomon, S D – sequence: 11 givenname: V surname: Kutyifa fullname: Kutyifa, V – sequence: 12 givenname: A surname: Kovacs fullname: Kovacs, A – sequence: 13 givenname: A surname: Kosztin fullname: Kosztin, A – sequence: 14 givenname: B K surname: Merkely fullname: Merkely, B K |
BookMark | eNo1kEtOwzAURS0EEm1hBwy8AFJsx27iYSnlI1UCQTqOLOe5MUrsyE6Qsiq2SKqW0buTd8_VmaNL5x0gdEfJkhKZPsAQfKc0TEEBJWzJJb9AMypSljAi2eWUiZSJoExeo3mM34SQjEkxQ79FDRiMAd1jb7BWobJK4wBxdLoO3tmoeusd7msIqhvx0B2CqgCb4Fsc7KHu8Q-4Plg9NCrgaYZ1Bzw9xLHtet9GrFyFzeD0sUY1WDfWWT0FP_TatxDvj7Sh6eOpcwLhx_3T-mP7VSSbzwLvz8SJoZobdGVUE-H2fBeoeN4Wm9dk9_7ytlnvEi0pT9JcUEI1aMhFBiSlcsU5GMayiq8yDYQxqXJOJM1WRrA8E2kFVKhcEC5ICukC8VOtDj7GAKbsgm1VGEtKyqPz8t95eXZeTs7TP5vjfeg |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.1093/europace/euae102.494 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1532-2092 |
ExternalDocumentID | 10_1093_europace_euae102_494 |
GroupedDBID | --- .2P .I3 .XZ .ZR 0R~ 2WC 4.4 48X 53G 5GY 5VS 5WA 6PF 70D AABZA AACZT AAJKP AAMVS AAOGV AAPNW AAPQZ AAPXW AASNB AAUAY AAVAP AAWTL AAYXX ABEUO ABIXL ABJNI ABKDP ABNHQ ABNKS ABPTD ABQLI ABWST ABXVV ABZBJ ACGFS ACPRK ACUFI ACUTO ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADJQC ADOCK ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEJOX AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AFXEN AGINJ AGKEF AGQXC AGSYK AGUTN AHMBA AHXPO AIJHB AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM CDBKE CITATION CS3 CZ4 DAKXR DILTD DU5 D~K E3Z EBD EBS EE~ EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H5~ HAR HW0 HZ~ IOX J21 KOP KQ8 KSI KSN M-Z MHKGH N9A NGC NOMLY NOYVH O9- OAUYM OAWHX ODMLO OJQWA OJZSN OK1 OPAEJ P2P PAFKI PEELM PQQKQ Q1. Q5Y RD5 RHF ROL ROX RPM RUSNO RW1 RXO SEL SV3 TCURE TJX TOX TR2 VVN WOQ X7H YAYTL YKOAZ YXANX ZKX ~91 |
ID | FETCH-LOGICAL-c914-385101cece857e0319644ef227d467ce0229a8409176f528753de15a8504503e3 |
ISSN | 1099-5129 |
IngestDate | Fri Aug 23 01:58:00 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Supplement_1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c914-385101cece857e0319644ef227d467ce0229a8409176f528753de15a8504503e3 |
OpenAccessLink | https://academic.oup.com/europace/article-pdf/26/Supplement_1/euae102.494/57876029/euae102.494.pdf |
ParticipantIDs | crossref_primary_10_1093_europace_euae102_494 |
PublicationCentury | 2000 |
PublicationDate | 2024-05-24 |
PublicationDateYYYYMMDD | 2024-05-24 |
PublicationDate_xml | – month: 05 year: 2024 text: 2024-05-24 day: 24 |
PublicationDecade | 2020 |
PublicationTitle | Europace (London, England) |
PublicationYear | 2024 |
SSID | ssj0007295 |
Score | 2.4482598 |
Snippet | Abstract
Background
Based on the results of the BUDAPEST-CRT Upgrade trial, in patients with intermittent or permanent right ventricular (RV) pacing and... |
SourceID | crossref |
SourceType | Aggregation Database |
Title | The effect of cardiac resynchronisation therapy upgrade from right ventricular pacing on symptoms and functional clinical outcomes, results from the BUDAPEST-CRT Upgrade trial |
Volume | 26 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKIiEuiKd4aw7cgnebxHn4uCxFFVIB0VT0FjmOAwg2rdpEqPun-Dv8HMaPtClbIZZLFEWpHXc-eR7-ZoaQF3El0RCIC1olQ0WZX6U0LQNOKxnzyi9Uykwvgsm7eDxjb-fRfDD41WMttU1xLC8O5pX8j1TxGcpVZ8leQbLbQfEB3qN88YoSxus_y9gSMgw73AhbV2Reb2ppit5aqo5nk6w2Xrv8vBKlsjklxi33NN3RxAB1yWshDQe69tab82WzOLf1m7XqcxHDbR7lom1wQXaLwfna7816l6nyavb69MNomtGzj5k3c3Oa9iCXzgGEVAebivQCFBO1-mapBKMdPXmso05ij_A4vfiqU-b2IrxT-eWHWjUuqeeTe9kFOQKmz-dtbrXbl3UhUW2bWLXV7dUBwoHvbeY2_d6B1jRGNVHW3D-oLmwpLeXWa26FQpPrmNnOy_v1uf_Qm1s2oz3HD_NunNyNkuMo18j1IOGRJptm7-dbGwFdmsicw7tldUmdPDzpRjnpfUvPaOpZP9ltcsu5LXBqMXiHDFR9l9yYOGLGPfIToQgWirCowEERLkERHBTBQRE0aMBAEXpQBAtFwB90UAREBeygCB0UoYPiS3BAtGPiRNAHIjggggHifZK9GWVnY-p6gVDJfUbDVOsOqXST3UQNTRk5pqogSErU9FKhJcqFjlX4SVxFgXbCS-VHIo3QZRmGKnxAjupFrR4S4FprDQOZMuWzqhSCh4JJ9OoLnEQE_BGh3X-dL23Fl_xvEn58xfefkJs7hD8lR82qVc_QsG2K5wYjvwHpB62Z |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Oxford University Press |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+effect+of+cardiac+resynchronisation+therapy+upgrade+from+right+ventricular+pacing+on+symptoms+and+functional+clinical+outcomes%2C+results+from+the+BUDAPEST-CRT+Upgrade+trial&rft.jtitle=Europace+%28London%2C+England%29&rft.au=Merkel%2C+E+D&rft.au=Hatala%2C+R&rft.au=Szigeti%2C+M&rft.au=Schwertner%2C+W+R&rft.date=2024-05-24&rft.issn=1099-5129&rft.eissn=1532-2092&rft.volume=26&rft.issue=Supplement_1&rft_id=info:doi/10.1093%2Feuropace%2Feuae102.494&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_europace_euae102_494 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1099-5129&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1099-5129&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1099-5129&client=summon |